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Background: To estimate the risk of radiation induced second cancers after radiotherapy using deep-inspiration
breath-hold (DI) technique with three-dimensional conformal (3DCRT) and volumetric arc therapy (VMAT) for
patients with Hodgkin’s lymphoma (HL).
Methods: Early-stage HL with mediastinal and supraclavicular involvement was studied using an Alderson phantom. A
whole body CT was performed and all tissues were delineated. The clinical target volumes and planning target volumes
(PTV) were determined according to the German Hodgkin study group guidelines. Free-breathing (FB) technique and DI
technique were simulated by different safety margins for the PTV definition. In both cases, 30 Gy in 15 fractions was
prescribed. Second cancer risk was estimated for various tissues with a second cancer model including fractionation.
Results: When compared with FB-3DCRT, estimated relative life time attributable risk (LAR) of cancer induction after
DI-3DCRT was 0.86, 0.76, 0.94 and 0.92 for breast, lung, esophagus and stomach, respectively. With DI-VMAT, the
corresponding values were 2.05, 1.29, 1.01, 0.93, respectively. For breast cancer, the LAR observed with DI-VMAT
was not substantially distinguishable from the LAR computed for mantle RT with an administered dose of 40 Gy.
Conclusions: This study suggests that DI may reduce the LAR of secondary cancers of all OARs and may be a
valuable technique when using 3DCRT. Conversely, VMAT may increase substantially the LAR and should be
cautiously implemented in clinical practice.Background
Early-stage Hodgkin’s lymphoma (HL) patients treated with
a combination of chemotherapy and radiotherapy have an
excellent clinical outcome, with overall survival of approxi-
mately 90% [1]. As a result, increased attention has focused
on long-term toxicity of HL treatment. Treatment-induced
complications, including but not limited to endocrinopathy,
cardio-vascular disease and secondary malignancies, can
induce substantial morbidity and significantly affect the
quality of life of HL survivors [2]. With increasing follow-up
after treatment, mortality from second cancers ultimately
surpasses that of HL [3]. Consequentially, the current
radiation therapy planning paradigm for the treatment* Correspondence: uwe.schneider@uzh.ch
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unless otherwise stated.of HL, is a reduction of field size, as randomized prospect-
ive trials have shown that regional therapy (i.e. involved-
field radiotherapy, IFRT) is as effective as extended-field
radiotherapy. To capitalize the potential decrease of
toxicity with IFRT, further field reduction, including
only the involved-nodes (INRT) in the target volume,
has been advocated. INRT should further decrease the
late radiation-induced toxicity [4,5] and diminish the
likelihood of secondary tumors [6].
Another possibility to further reduce the target volume
and thus the irradiated volume is the use of gating
techniques such as deep-inspiration breath-hold (DI). DI
techniques can be implemented with intensity modulation
techniques, such as volumetric arc therapy (VMAT).
Recently it was shown [7] that radiation exposure of the
coronary arteries, heart, and lungs in patients with medi-
astinal Hodgkin’s lymphoma was greatly reduced using DIral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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VMAT. The greatest benefit was obtained for tumors
in the upper part of the mediastinum [7]. In another
study Charpentier et al. [8] have shown that the com-
bination of DI and parallel-opposed beam radiotherapy
can significantly reduce lung and heart dose, however,
has the potential to increase breast dose in females.
The aim of this phantom-based-study was to perform a
second cancer risk comparison, using three-dimensional
conformal radiotherapy (3DCRT) and VMAT and two
planning paradigms for HL, namely free-breathing (FB)
INRT and DI INRT.
Methods
Patient model
The Alderson Rando Phantom with a 200 ml breast at-
tachment was used to represent a young female Hodgkin
patient. It was decided to use a phantom instead of real
patient data since a high resolution whole body CT could
be performed. In addition the Alderson phantom is used
for detailed stray dose measurements in our institution
[9,10] which are employed later in this work to reconstruct
a precise dose distribution. It was our study funding hy-
pothesis that the advantage of a precise high resolution dose
distribution as the basis for second cancer induction calcu-
lations outperforms the disadvantage of real patient data.
The 3D cube was reconstructed in a 512 × 512 matrix
with a resolution of 0.12 cm in the x,y plane and a z-axis
resolution of 0.5 cm. The phantom was manually seg-
mented as a computerized 3-dimensional volume array,
modeling of all major internal structures of the body.
Target volume delineation
The target volumes, were delineated on the bases of real
patient data according to the German Hodgkin Study
Group (http://www.ghsg.org) guidelines [11]. More spe-
cifically, the clinical tumor volume (CTV) was the initial
morphological volume of the initial mediastinal and/or
supraclavicular mass with a significant PET uptake ob-
served in the pre-chemotherapy diagnostic CT and PET.
The real patient data were matched to the CT of the
Alderson Rando phantom for delineation of the target
structures. Delineation was performed by the same radi-
ation oncologist (MS) who did the segmentation of the
healthy structures. Four different lymph node involve-
ments were studied: mediastinal both sides, mediastinal
and supraclavicular both sides, mediastinal both sides
and supraclavicular left, and mediastinal left.
PTVs for the four different involvements were created
on the bases of the German Hodgkin disease study
protocols by using 3 cm margins in the cranial-caudal
direction and 1.5 cm in the lateral direction for FB
[11]. DI was simulated by reducing the margins according
to Wong et al. [12] to 1 cm and 0.5 cm, respectively. Thecorresponding volumes for FB and DI were 611.9 cm3 and
322.2 cm3 for mediastinal both sides, 1153.6 cm3 and
433.6 cm3 for mediastinal and supraclavicular both sides,
882.7 cm3 and 375.6 cm3 for mediastinal both sides and
supraclavicular left, and 291.9 cm3 and 126.1 cm3 for
mediastinal left.
In addition to the INRT targets, IFRT targets and
classical mantle fields were defined to test the second
cancer calculations with historical data. The planning
target volume for IFRT was derived from the Ann Arbor
Staging system.
Treatment planning
Both FB-INRT and DI-INRT were planned to deliver
30 Gy in 2 Gy fractions to PET- & CT-defined target
volumes (Figure 1). Treatment planning was performed
on the basis of the German Hodgkin disease study pro-
tocols (http://www.ghsg.org). We used for treatment
planning the Eclipse External Beam Planning system
version 10.0 (Varian Oncology Systems, Palo Alto, CA)
using the AAA-algorithm (version 10.0.28) with corrected
dose distributions for head-, phantom- and collimator-
scatter [9,10]. All 3DCRT plans were calculated with 6
MV photons and consisted of two isocentrical anterior-
posterior (AP/PA) opposed fields. In addition volumetric
arc intensity modulated treatment (VMAT) was planned
for the DI target volumes using two 360° rotation for the
bi-lateral involvements and two 180° arcs for the homo-
lateral involvements with the dose constraints listed in [4].
The corresponding conformity index according to RTOG
for FB-VMAT and DI-VMAT was 1.00 and 1.03 for medi-
astinal both sides, 1.00 and 1.05 for mediastinal and supra-
clavicular both sides, 0.97 and 0.99 cm3 for mediastinal
both sides and supraclavicular left, and 0.99 and 1.04 for
mediastinal left.
For the comparison with historical data a classical
mantle field irradiation was planned on the basis of the
review by Hoppe [13]. The fields were arranged with 6
MV radiation and equal field weights from 0° and 180°
at a distance of 100 cm (SSD). The dose prescription of
the mantle field was 40 Gy in 2 Gy fractions. In addition,
also with 40 Gy prescription, several IFRTs (Supraclavicu-
lar/neck, Axillary + Mediastinal/homolateral, Axillary +
Mediastinal/bilateral, Axillary no Mediastinal involvement)
were planned.
Differential dose-volume histograms (DVH) were ex-
tracted from the treatment planning system and were
used for the second cancer risk calculations.
Estimation of second cancer risk
The carcinogenesis model [14-16] used in the estimation
of the risk of second primary malignancies emphasizes the
cell kinetics of radiation induced cancer by mutational
processes. Briefly, the model integrates cell sterilization
Figure 1 Illustration of the four INRT-PTV in a transversal (left)
and frontal (right) slice: (A) mediastinal both sides, (B) mediastinal
and supraclavicular both sides, (C) mediastinal both sides and
(D) supraclavicular left, and mediastinal. The white bold line shows
the FB target and the white line the DI target.
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repopulation effects. The model parameters were ob-
tained by fits to several epidemiological, cancer specific
carcinogenesis data [17-19] for carcinoma and sarcoma
induction. Radiation induced lung cancer estimates were
determined with the obtained model parameters from
[17], breast cancer estimates from [18] and esophagus,
stomach, thyroid, soft tissues and bone from [19]. Soft
tissue sarcoma induction was estimated on the basis of
the DVH for all normal tissues without the segmentedorgans and bone. For bone sarcoma induction, the DVH
of the complete bone structure was used.
From the DVHs of the structures of interest, organ
equivalent dose was calculated [15]. Organ equivalent
dose was converted to excess absolute risk for a western
population for each organ and for all organs together
[14]. The resulting life time cancer risk for a patient
from the specific radiotherapy treatment was determined
by life time attributable risk (LAR) according to Kellerer
et al. [20] by an integration of excess absolute risk from
the age at exposure to the life time expectancy. LAR
was calculated either as a function of age at exposure or
was computed for one specific age at diagnosis of HL
(20 years).
LAR is a life time risk and not applicable to epidemio-
logical studies which include subjects with limited follow-
up time. Therefore, cumulative risk is determined for
these patients by taking into account the follow-up time
instead of the life expectancy.
Base line risks for the different cancer sites were taken
from Bray et al. [21] for the European union cohort.
Epidemiological data
The second cancer model was tested with breast cancer
data from two epidemiological studies from historical
Hodgkin’s disease treatments. Hodgson et al. [22] studied
the cumulative incidence for second cancers for specific
attained ages and ages at Hodgkin’s disease diagnosis.
They identified 850 excess second cancers from 18862
5-year Hodgkin’s survivors. They obtained cumulative
risk for second breast cancer as a function of attained
age for female Hodgkin patients diagnosed at the age of
20 [23]. We adjusted the data from Table 1 of Hodson
et al. [22] to the baseline risks of the European Union
and compared them with our findings.
The second comparison was performed with the re-
sults of the study of De Bruin et al. [24]. They accessed
the long-term risk of breast cancer after treatment for
Hodgkin’s lymphoma and focused on the volume of
breast tissue exposed to radiation. They found that
mantle field irradiation (involving the axillary, medias-
tinal, and neck nodes) was associated with a 2.7-fold
increased risk (95% CI, 1.1 to 6.9) compared with simi-
larly dosed (36 to 44 Gy) mediastinal irradiation alone
(see Table 2).
Results
Modeled risk compared to epidemiological data
In Table 2 the observed excess risk from De Bruin et al.
[24] of radiation induced breast cancer is listed relative
to mediastinal IFRT. In the same table the modeled
relative LAR is listed for a age at exposure of 20 years.
Cumulative absolute risk of radiation induced breast
cancer as a function of attained age is plotted in Figure 2
Table 1 Lifetime attributable risk for DI-3DCRT and
DI-VMAT relative to a free-breathing 3DCRT for INRT












3DCRT 0.86 0.84 0.85 0.91
VMAT 2.05 1.82 1.89 1.93
Lung
3DCRT 0.76 0.80 0.78 0.74
VMAT 1.29 1.11 1.17 1.55
Esophagus
3DCRT 0.94 0.98 1.06 0.90
VMAT 1.01 1.12 1.15 1.00
Stomach
3DCRT 0.92 0.91 0.92 0.93
VMAT 0.93 0.93 0.93 0.92
Thyroid
3DCRT 0.89 0.61 0.62 0.93
VMAT 0.88 0.67 0.79 0.93
Bone sarcoma
3DCRT 0.88 0.87 0.82 0.88
VMAT 0.62 0.58 0.60 0.63
Soft tissue
sarcoma
3DCRT 0.89 0.83 0.83 0.90
VMAT 0.75 0.65 0.69 0.78
All cancers
3DCRT 0.82 0.82 0.82 0.86
VMAT 1.59 1.36 1.43 1.63
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The triangles represent the data from Hodson et al. [22]
for mantle field irradiation in comparison to the mod-
elled data for 40 Gy as the solid line. The dotted line
marks mediastinal IFRT with the prescribed dose ofTable 2 Test of the applied second cancer model by comparis
Planning paradigm Used treament plans Weight
to # tre
Mediastinal Mediastinal 109
Mantle Mantle field alone 637
Other Supradiaphragmatic Supraclavicular/neck 34
Axillary + Mediastinal/homolat 41
Axillary + Mediastinal/bilat 7
Axillary, no Media. 14
Total 96
Modeling was performed with a total dose of 40 Gy delivered in 2 Gy fractions.40 Gy. If INRT is applied to reduce further the irradi-
ated volume but keeping the dose at 40 Gy the corre-
sponding risk is shown as the dashed line in Figure 2.
An additional dose reduction with INRT to 30 Gy is
represented by the dashed-dotted line. The baseline
risk is plotted as the diamonds.
The risk of second breast cancer induction was halved
(age 20: 0.5, age 50: 0.5, age 80: 0.6) with the change
from mantle field irradiation to the treatment of HL by
reducing the field size and keeping the dose constant
(Figure 2). Further reduction of field size by applying
INRT has the potential to reduce breast cancer induc-
tion by approximately 30%. An INRT dose reduction
from 40 Gy to 30 Gy could reduce radiation risk further
by 10%.Potential of DI radiotherapy
DI 3DCRT has the potential to further reduce breast
cancer risk by 15% when mediastinal lymph nodes are
treated. However, VMAT increased the cumulative ab-
solute risk of breast cancer induction by 100% with DI
mediastinal INRT.
Table 1 details the LAR relative to FB- and DI-3DCRT/
VMAT for breast, lung, esophagus, stomach, thyroid, soft
tissue sarcoma and bone sarcoma for 30 Gy INRT. The
excess relative risk is calculated for mediastinal treatment
on both sides, mediastinal and supraclavicular RT on both
sites, mediastinal on both sides combined with supracla-
vicular involvement on the left side and a homolateral
mediastinal involvement of the left side. The excess
relative risk is more or less independent of lymph node
involvement. Radiotherapy using DI-3DCRT techniques
have the potential to improve second cancer induction
rates by more than 15% with a variation from 40% for
thyroid to 0% for esophagus. Although, DI-VMAT can
reduce soft tissue and bone sarcoma risk by 30-40%,
overall a 50% increase of LAR of solid cancer induction
can be expected. This is due to the low absolute risks










Figure 2 Plot of cumulative absolute risk of radiation induced breast cancer as a function of attained age for a 20 year old female patient.
The triangles represent the data from Hodson et al. [23] for mantle field irradiation in comparison with the modelled data for 40 Gy as the solid line.
The dotted line marks mediastinal IFRT with the prescribed dose of 40 Gy. A volume reduction with 40 Gy INRT is shown as the dashed line and an
additional dose reduction to 30 Gy is represented by the dashed-dotted line. Baseline risk is plotted as the diamonds.
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patient treated at the age of 20 is plotted in Figure 3 for the
different lymph node involvements. Clearly DI-3DCRT has
the potential to decrease the risk of cancer induction. How-
ever DI-VMAT is, regarding to secondary malignancy, the
inferior treatment option.
In Figure 4 LAR for breast cancer is plotted as a function
of age at exposure for a mantle field treatment with 40 Gy
(dashed-dotted line), a free-breathing 3DCRT treatment at
30 Gy (solid line), a DI-3DCRT at 30 Gy (dotted line) and
a DI-VMAT treatment at 30 Gy (dashed-dotted line).
Two effects can be observed. First, in absolute terms,Figure 3 Plot of LAR in% for all solid cancers analysed in this work. F
involvements mediastinal both sides, mediastinal and supraclavicular both site
the left side and a homolateral mediastinal involvement of the left side.DI-VMAT has a detrimental effect on cancer induction,
even with a INRT paradigm, as the second cancer risk is
almost as large as with a large mantle field irradiation.
Secondly, age of exposure is an extremely important
parameter regarding radiation induced cancer. One
result of the calculations (Figure 4) is that LAR of breast
cancer is more than two times larger for a HL patient
treated at the age of 20 than for a 50 year old patient.
Discussion
Late toxicities, especially radiation induced second cancers,
are of major concern in patients treated for Hodgkin’sB-3DCRT is compared to DI-3DCRT and DI-VMAT for the lymph node
s, mediastinal both sides combined with supraclavicular involvement on
Figure 4 LAR for breast cancer plotted as a function of age at exposure for a mantle field treatment with 40 Gy (dashed-dotted line),
a FB-3DCRT treatment at 30 Gy (solid line), a DI-3DCRT at 30 Gy (dotted line) and a DI-VMAT treatment at 30 Gy (dashed line). Baseline risk
is plotted as the diamonds.
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http://www.ro-journal.com/content/9/1/58lymphoma [22,24]. To reduce the incidence of second
cancer induction after radiation therapy, two possibilities
can be explored: reducing the total radiation dose and re-
ducing the volume (i.e. IFRT, INRT, DI). Our data suggest
that volume reduction is the most effective way to reduce
the number of secondary malignancies. LAR for a 20 year
old patient relative to a historical mantle treatment is: 0.61
for IFRT 40 Gy, 0.55 for IFRT 30 Gy and 0.45 for INRT
30 Gy (Figure 2). A further reduction of the treated
volume can be achieved by using deep-inspiration
breath-hold technique which can reduce further cancer
risk to 0.38 relative to a mantle field treatment.
When DI techniques are used to treat Hodgkin’s patients
it is also possible to use intensity modulation techniques.
Goodman et al. [25] published their experience with IMRT
in HL and non-HL involving the mediastinum. They dem-
onstrated that IMRT was able to reduce the dose delivered
to the heart and the lungs in comparison with conventional
parallel-opposed fields and 3DCRT. Recently Paumier et al.
[7] found similar results: radiation exposure of the coronary
arteries, heart, and lungs in patients with mediastinal
Hodgkin’s lymphoma was greatly reduced using DI with
IMRT. Despite the obvious advantage to reduce side effects
related to the heart and the coronary arteries in Hodgkin’s
patients, an open question is the impact of intensity modu-
lation techniques on the incidence of second malignancies.
We could show that DI-VMAT has the potential to
increase life time attributable risk relative to a historical
mantle treatment to 0.91 and thus nearly outbalance the
advantages which was gained with the current paradigm of
volume and dose reduction. Regarding second cancerinduction VMAT techniques have solely an advantage
regarding sarcoma induction, as sarcomas occur usually in
heavily irradiated volumes and the volumetric modulation
technique is modifying the dose distribution from high-
dose-small-volume to low-dose-large-volume. However,
since the incidence of sarcomas is small when compared to
carcinoma induction, the impact on the total risk for
radiation induced cancer is small.
Although it was shown in this work that DI-VMAT is
inferior to classical parallel opposed treatment techniques
with regard to second cancer induction it should be noted
that VMAT techniques, gated or non-gated, ameliorate
the deterministic toxicity profile. It was shown [26-28],
that the application of VMAT techniques can result in
better dose spearing of the thyroid gland, the heart and
the coronary ostia.
The results of this study are based on a model that, while
improved over older secondary malignancy models by
including fractionation, excludes potential confounding
factors that may affect secondary lung and breast malig-
nancy risk. These potential factors include family history,
chemotherapy use and environmental factors like smoking.
In this work it was decided to use an Alderson Rando
phantom for treatment planning because it has the advan-
tage that precise dose information including stray doses on
a high resolution whole body CT can be used for second
cancer calculations. However, the use of a phantom instead
of patient data has two disadvantages. First, a phantom is
not accounting for the variation in anatomy between
patients. Second, the simulated DI technique affects only
the size of the PTV. However, the use of the DI technique
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due to the anatomical changes of free breathing when com-
pared to deep inspiration. Thus, the additional sparing of
organs at risk achieved with DI is not simply due to smaller
PTVs. This additional volume reduction was not considered
in this work and thus further patient studies are needed to
explore second cancer induction in Hodgkin’s patients in
more detail.
Conclusion
The additional volume reduction by applying DI 3DCRT of
HL patients has the potential to further minimize life time
second cancer risk (LAR) to 0.38 relative to a historical
mantle treatment. This is an additional 15% reduction due
to the use of DI.
The combined use of VMAT with DI allows significant
sparing of the organs at risk like the coronary arteries and
the heart in comparison with 3DCRT. However, second can-
cer risk is substantially increased to 0.91 when compared to
40 Gy administered with a 2D mantle field technique. Thus
the risk-gain due to volume and dose reduction is almost
negatively balanced by the application of volumetric modu-
lation techniques.
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